PMID- 35407665
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220419
IS  - 2077-0383 (Print)
IS  - 2077-0383 (Electronic)
IS  - 2077-0383 (Linking)
VI  - 11
IP  - 7
DP  - 2022 Apr 6
TI  - Impact of Liver Fibrosis on Survival of Patients with Intrahepatic 
      Cholangiocarcinoma Receiving Gemcitabine-Based Chemotherapy.
LID - 10.3390/jcm11072057 [doi]
LID - 2057
AB  - Intrahepatic cholangiocarcinoma (iCCA) is the most frequent subtype of 
      cholangiocarcinoma (CCA), and the incidence has globally increased in recent 
      years. In contrast to surgically treated iCCA, data on the impact of fibrosis on 
      survival in patients undergoing palliative chemotherapy are missing. We 
      retrospectively analyzed the cases of 70 patients diagnosed with iCCA between 
      2007 and 2020 in our tertiary hospital. Histopathological assessment of fibrosis 
      was performed by an expert hepatobiliary pathologist. Additionally, the 
      fibrosis-4 score (FIB-4) was calculated as a non-invasive surrogate marker for 
      liver fibrosis. For overall survival (OS) and progression-free survival (PFS), 
      Kaplan-Meier curves and Cox-regression analyses were performed. Subgroup analyses 
      revealed a median OS of 21 months (95% CI = 16.7-25.2 months) and 16 months (95% 
      CI = 7.6-24.4 months) for low and high fibrosis, respectively (p = 0.152). In 
      non-cirrhotic patients, the median OS was 21.8 months (95% CI = 17.1-26.4 
      months), compared with 9.5 months (95% CI = 4.6-14.3 months) in cirrhotic 
      patients (p = 0.007). In conclusion, patients with iCCA and cirrhosis receiving 
      palliative chemotherapy have decreased OS rates, while fibrosis has no 
      significant impact on OS or PFS. These patients should not be prevented from 
      state-of-the-art first-line chemotherapy.
FAU - Kinzler, Maximilian N
AU  - Kinzler MN
AD  - Department of Internal Medicine I, University Hospital Frankfurt, Goethe 
      University Frankfurt, 60590 Frankfurt am Main, Germany.
FAU - Klasen, Christina
AU  - Klasen C
AD  - Department of Internal Medicine I, University Hospital Frankfurt, Goethe 
      University Frankfurt, 60590 Frankfurt am Main, Germany.
FAU - Schulze, Falko
AU  - Schulze F
AD  - Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Goethe 
      University Frankfurt, 60590 Frankfurt am Main, Germany.
FAU - Herrmann, Eva
AU  - Herrmann E
AD  - Institute of Biostatistics and Mathematical Modelling, Goethe University 
      Frankfurt, 60590 Frankfurt am Main, Germany.
FAU - Schnitzbauer, Andreas A
AU  - Schnitzbauer AA
AD  - Department of General, Visceral, Transplant and Thoracic Surgery, University 
      Hospital Frankfurt, Goethe University Frankfurt, 60590 Frankfurt am Main, 
      Germany.
FAU - Trojan, Jorg
AU  - Trojan J
AD  - Department of Internal Medicine I, University Hospital Frankfurt, Goethe 
      University Frankfurt, 60590 Frankfurt am Main, Germany.
FAU - Zeuzem, Stefan
AU  - Zeuzem S
AD  - Department of Internal Medicine I, University Hospital Frankfurt, Goethe 
      University Frankfurt, 60590 Frankfurt am Main, Germany.
FAU - Wild, Peter J
AU  - Wild PJ
AD  - Dr. Senckenberg Institute of Pathology, University Hospital Frankfurt, Goethe 
      University Frankfurt, 60590 Frankfurt am Main, Germany.
AD  - Wildlab, University Hospital Frankfurt MVZ GmbH, 60590 Frankfurt am Main, 
      Germany.
FAU - Walter, Dirk
AU  - Walter D
AD  - Department of Internal Medicine I, University Hospital Frankfurt, Goethe 
      University Frankfurt, 60590 Frankfurt am Main, Germany.
LA  - eng
PT  - Journal Article
DEP - 20220406
PL  - Switzerland
TA  - J Clin Med
JT  - Journal of clinical medicine
JID - 101606588
PMC - PMC8999345
OTO - NOTNLM
OT  - chemotherapy
OT  - intrahepatic cholangiocarcinoma
OT  - liver fibrosis
OT  - overall survival
COIS- J.T. received honoraria for consulting and advisory board role from Amgen, Astra 
      Zeneca, Bayer Healthcare, Bristol Myers-Squibb, Eisai, Ipsen, Merck Serono, Merck 
      Sharp & Dome, Lilly Imclone, Roche and Servier.
EDAT- 2022/04/13 06:00
MHDA- 2022/04/13 06:01
PMCR- 2022/04/06
CRDT- 2022/04/12 01:07
PHST- 2022/03/11 00:00 [received]
PHST- 2022/03/31 00:00 [revised]
PHST- 2022/04/04 00:00 [accepted]
PHST- 2022/04/12 01:07 [entrez]
PHST- 2022/04/13 06:00 [pubmed]
PHST- 2022/04/13 06:01 [medline]
PHST- 2022/04/06 00:00 [pmc-release]
AID - jcm11072057 [pii]
AID - jcm-11-02057 [pii]
AID - 10.3390/jcm11072057 [doi]
PST - epublish
SO  - J Clin Med. 2022 Apr 6;11(7):2057. doi: 10.3390/jcm11072057.